← do dużych inwestorów
Samsara BioCapital, LLC
inwestor instytucjonalny · portfel $1.22 mld · 24 pozycji · raport na 30.06.2026
Pozycje w akcjach raport za 30.06.2026, złożony 14.08.2026; zmiana — względem 31.03.2026 · 26
| Spółka | Akcje | Wartość | % portfela | Zmiana kwartalna |
|---|---|---|---|---|
| Scholar Rock Holding Corp US:SRRK | 6 897 652 | $379 mln | 31.16% | — |
| Alumis Inc US:ALMS | 6 345 219 | $179 mln | 14.67% | — |
| Mineralys Therapeutics, Inc. US:MLYS | 5 871 018 | $158 mln | 13.01% | — |
| Septerna, Inc. US:SEPN | 3 149 128 | $105 mln | 8.66% | — |
| Alamar Biosciences, Inc. US:ALMR | 2 480 310 | $67.2 mln | 5.52% | nowa |
| Neurogene Inc US:NGNE | 1 717 127 | $54.0 mln | 4.44% | — |
| Kalaris Therapeutics, Inc. US:KLRS | 12 881 175 | $52.4 mln | 4.31% | −66 906 |
| SpyGlass Pharma, Inc. US:SGP | 2 109 953 | $47.0 mln | 3.86% | — |
| Sutro Biopharma US:STRO | 1 062 872 | $35.3 mln | 2.90% | — |
| INVENTIVA US:IVA | 6 314 805 | $23.9 mln | 1.96% | +1 120 000 |
| Jade Biosciences, Inc. US:JBIO | 736 237 | $16.4 mln | 1.34% | −232 561 |
| Parabilis Medicines, Inc. US:PBLS | 556 044 | $15.2 mln | 1.25% | nowa |
| vTv Therapeutics Inc US:VTVT | 298 496 | $11.2 mln | 0.92% | — |
| Aquestive Therapeutics, Inc. US:AQST | 2 500 000 | $10.4 mln | 0.85% | — |
| Nkarta Inc US:NKTX | 3 507 666 | $9.93 mln | 0.82% | — |
| Artiva Biotherapeutics, Inc. US:ARTV | 954 861 | $9.26 mln | 0.76% | nowa |
| Rani Therapeutics Holdings I… US:RANI | 10 369 159 | $7.88 mln | 0.65% | +1 869 159 |
| AgomAb Therapeutics NV US:AGMB | 600 000 | $7.79 mln | 0.64% | — |
| ABIVAX US:ABVX | 55 095 | $7.34 mln | 0.60% | −1 486 |
| X4 Pharmaceuticals Inc US:XFOR | 1 395 587 | $6.52 mln | 0.54% | −436 979 |
| Eloxx Pharmaceuticals, Inc. US:ELOX | 400 000 | $5.55 mln | 0.46% | nowa |
| Coherus BioSciences Inc US:CHRS | 3 428 571 | $4.80 mln | 0.39% | — |
| Upstream Bio, Inc. US:UPB | 353 717 | $2.45 mln | 0.20% | −382 330 |
| GOSSAMER BIO INC CUSIP 38341P102 | 7 222 559 | $1.19 mln | 0.10% | — |
| ARCELLX INC CUSIP 03940C100 | 0 (było 60 873) | — | — | sprzedana |
| Palvella Therapeutics, Inc US:PVLA | 0 (było 38 432) | — | — | sprzedana |
W spółkach z naszej bazy 16
| Spółka | Udział | Akcje | Data raportu |
|---|---|---|---|
| Kalaris Therapeutics, Inc. | 54.11% | 12 881 175 | 2026-06-30 |
| Eloxx Pharmaceuticals, Inc. | 12.73% | 400 000 | 2026-06-30 |
| Rani Therapeutics Holdings I… | 8.98% | 10 369 159 | 2026-06-30 |
| Neurogene Inc | 8.58% | 1 717 127 | 2026-06-30 |
| vTv Therapeutics Inc | 7.44% | 298 496 | 2026-06-30 |
| Septerna, Inc. | 6.75% | 3 149 128 | 2026-06-30 |
| Mineralys Therapeutics, Inc. | 6.64% | 5 871 018 | 2026-06-30 |
| Sutro Biopharma | 6.41% | 1 062 872 | 2026-06-30 |
| SpyGlass Pharma, Inc. | 6.31% | 2 109 953 | 2026-06-30 |
| Alumis Inc | 4.9% | 6 345 219 | 2026-06-30 |
| Nkarta Inc | 4.9% | 3 507 666 | 2026-06-30 |
| Coherus BioSciences Inc | 4.44% | 6 857 142 | 2026-06-30 |
| Alamar Biosciences, Inc. | 3.57% | 2 480 310 | 2026-06-30 |
| INVENTIVA | 3.02% | 6 314 805 | 2026-06-30 |
| Odonate Therapeutics | 2.38% | 700 421 | 2022-03-31 |
| Artiva Biotherapeutics, Inc. | 1.95% | 954 861 | 2026-06-30 |
reklama
